{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:31:40Z","timestamp":1778761900588,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cca.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T10:47:50Z","timestamp":1642416470000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The role of serum free light chain as biomarker of Myasthenia Gravis"],"prefix":"10.1016","volume":"528","author":[{"given":"Caterina Maria","family":"Gambino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Agnello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Lo Sasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria Vincenza","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Candore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela Maria","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Vidali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cca.2022.01.004_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.cca.2022.01.004_b0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0404.1994.tb02731.x","article-title":"Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy","volume":"90","author":"Tola","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.cca.2022.01.004_b0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2022.01.004_b0020","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1056\/NEJMc1701027","article-title":"Myasthenia Gravis","volume":"376","author":"Gilhus","year":"2017","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.cca.2022.01.004_b0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"10.1016\/j.cca.2022.01.004_b0030","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"issue":"12","key":"10.1016\/j.cca.2022.01.004_b0035","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cca.2022.01.004_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.cca.2022.01.004_b0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.cca.2022.01.004_b0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2022.01.004_b0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2022.01.004_b0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1373\/clinchem.2005.048017","article-title":"Serum free light chain measurements move to center stage","volume":"51","author":"Bradwell","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2022.01.004_b0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M5-4","article-title":"Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?","volume":"5","author":"Brebner","year":"2013","journal-title":"F1000 Med. Rep."},{"issue":"1","key":"10.1016\/j.cca.2022.01.004_b0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"issue":"1-2","key":"10.1016\/j.cca.2022.01.004_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2022.01.004_b0080","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1515\/cclm-2016-1024","article-title":"Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays","volume":"55","author":"Palladini","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2022.01.004_b0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-017-8603-x","article-title":"Memory B Cells and Response to Abatacept in Rheumatoid Arthritis","volume":"53","author":"Gazeau","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.cca.2022.01.004_b0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12016-016-8568-1","article-title":"Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up","volume":"53","author":"Simonin","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.cca.2022.01.004_b0095","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaut.2010.07.005","article-title":"Aberrant expression of CD6 on B-cell subsets from patients with Sj\u00f6gren's syndrome","volume":"35","author":"Alonso","year":"2010","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.cca.2022.01.004_b0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12016-017-8604-9","article-title":"Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases","volume":"53","author":"Renaudineau","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"9","key":"10.1016\/j.cca.2022.01.004_b0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.cca.2022.01.004_b0110","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar2773","article-title":"Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort","volume":"11","author":"Gottenberg","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cca.2022.01.004_b0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ard.2006.052159","article-title":"Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome","volume":"66","author":"Gottenberg","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cca.2022.01.004_b0120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.201104-0761OC","article-title":"An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease","volume":"185","author":"Braber","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.cca.2022.01.004_b0125","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nm722","article-title":"Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses","volume":"8","author":"Redegeld","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2022.01.004_b0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cei.13385","article-title":"Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases","volume":"199","author":"Gulli","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cca.2022.01.004_b0135","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/labmed\/lmz073","article-title":"Clinical Use of \u03ba Free Light Chains Index as a Screening Test for Multiple Sclerosis","volume":"51","author":"Agnello","year":"2020","journal-title":"Lab Med."},{"key":"10.1016\/j.cca.2022.01.004_b0140","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/medicina55060245","article-title":"Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update","volume":"55","author":"Lo Sasso","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.cca.2022.01.004_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.cca.2022.01.004_b0150","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.cca.2022.01.004_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/joa.12034","article-title":"The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis","volume":"224","author":"Koneczny","year":"2014","journal-title":"J. Anat."},{"issue":"2","key":"10.1016\/j.cca.2022.01.004_b0160","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.cca.2022.01.004_b0165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cca.2022.01.004_b0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.31.3.282","article-title":"Myasthenia gravis: passive transfer to mice of antibody to human and mouse acetylcholine receptor","volume":"31","author":"Oda","year":"1981","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.cca.2022.01.004_b0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mus.880090404","article-title":"Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules","volume":"9","author":"Sterz","year":"1986","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.cca.2022.01.004_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9646209","article-title":"Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients","volume":"2018","author":"Basile","year":"2018","journal-title":"J Immunol. Res."},{"issue":"5","key":"10.1016\/j.cca.2022.01.004_b0185","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/NXI.0000000000000831","article-title":"High \u03ba free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis","volume":"7","author":"Wilf-Yarkoni","year":"2020","journal-title":"Neuroimmunol. Neuroinflamm."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:02:37Z","timestamp":1757862157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"alternative-id":["S0009898122000134"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.01.004","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of serum free light chain as biomarker of Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}